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Résumé en
anglais
Glioblastoma is the most common malignant adult brain tumor and has a very poor
patient prognosis. The mean survival for highly proliferative glioblastoma is only 10 to
14 months despite an aggressive current therapeutic approach known as Stupp's
protocol, which consists of debulking surgery followed by radiotherapy and
chemotherapy. Despite several clinical trials using anti-angiogenic targeted therapies,
glioblastoma medical care remains without major progress in the last decade. Recent
progress in nuclear medicine, has been mainly driven by advances in biotechnologies
such as radioimmunotherapy, radiopeptide therapy, and radionanoparticles, and these
bring a new promising arsenal for glioblastoma therapy. For therapeutic purposes,
nuclear medicine practitioners classically use β particle emitters like I, Y, Re, or Lu. In
the glioblastoma field, these radioisotopes are coupled with nanoparticles, monoclonal
antibodies, or peptides. These radiopharmaceutical compounds have resulted in a
stabilization and/or improvement of the neurological status with only transient side
effects. In nuclear medicine, the glioblastoma-localized and targeted internal
radiotherapy proof-of-concept stage has been successfully demonstrated using β
emitting isotopes. Similarly, α particle emitters like Bi, At, or Ac appear to be an
innovative and interesting alternative. Indeed, α particles deliver a high proportion of
their energy inside or at close proximity to the targeted cells (within a few
micrometers from the emission point versus several millimeters for β particles). This
physical property is based on particle-matter interaction differences and results in α
particles being highly efficient in killing tumor cells with minimal irradiation of
healthy tissues and permits targeting of isolated tumor cells. The first clinical trials
confirmed this idea and showed good therapeutic efficacy and less side effects, thus
opening a new and promising era for glioblastoma medical care using α therapy. The
objective of this literature review is focused on the developing field of nuclear
medicine and aims to describe the various parameters such as targets, vectors,
isotopes, or injection route (systemic and local) in relation to the clinical and
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